Evidence map›Paper›PMID 30421274›Full record

ArticleJournal of clinical immunology2018

Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals.

Chantal A Zuizewind, Paul van Kessel, Christine M Kramer, Mary M Muijs, Janneke C Zwiers, Mattanja Triemstra

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Journal of clinical immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Bringing the hospital home: exploring the challenges and perspectives of healthcare professionals on home treatment in hemato-oncology: a qualitative analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chantal A ZuizewindNIVEL, Netherlands Institute for Health Services Research, Otterstraat 118-124, 3513 CR, Utrecht, The Netherlands.
Paul van KesselNIVEL, Netherlands Institute for Health Services Research, Otterstraat 118-124, 3513 CR, Utrecht, The Netherlands.
Christine M KramerSanquin Plasma Products BV (SPP), Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
Mary M MuijsSanquin Plasma Products BV (SPP), Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
Janneke C ZwiersSanquin Plasma Products BV (SPP), Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
Mattanja TriemstraNIVEL, Netherlands Institute for Health Services Research, Otterstraat 118-124, 3513 CR, Utrecht, The Netherlands. m.triemstra@nivel.nl.ORCID 0000-0001-7133-6028
Netherlands Institute for Health Services Research · NLSanquin · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to evaluate home-based treatment with immunoglobulin (IgG) by assessing and comparing the experiences and perceived value of patients and healthcare professionals, and potential differences in experiences between subcutaneous (SCIg) and intravenous (IVIg) modes of administration. As choices on the location and type of treatment are determined in a shared decision-making process, we evaluated the home-based treatment from the perspectives of both patients and professionals.

methodsA questionnaire study was conducted among 205 patients, 44 informal caregivers, 43 hospital professionals, and 21 nurses of the Sanquin Home Service (SHS) that provides home treatment with immunoglobulins in the Netherlands. Experiences, perceived benefits, and effects on the patients' quality of life and overall ratings were assessed.

resultsBoth patients and professionals were predominantly positive about the home treatment, irrespective of the administration mode. The home-based treatment with Ig contributed to the patients' autonomy, participation, and perceived health. Patients and informal caregivers valued the treatment with a global rating of 8.84, and professionals with 8.32 (on a scale from 0 "worst" to 10 "best possible care"). SCIg and IVIg patient groups differed in their experiences regarding the accessibility and communication of the home treatment service. Furthermore, hospital professionals reported lower effects on quality of life than patients themselves.

conclusionsHome-based treatment with immunoglobulins is highly valued because of its personalized and effective character, meeting the needs and preferences of patients. Nonetheless, patients and professionals do have different perspectives on the value of this type of care.

Indexed as

AdolescentAdultAgedChildFemaleHealth PersonnelHome Care ServicesHumansImmune System DiseasesImmunoglobulin GImmunologic FactorsMaleMiddle AgedNetherlandsPatient PreferencePatientsImmunoglobulin GImmunologic Factorsevaluation studyhome infusion therapyImmunoglobulinsquality of lifeshared decision-makingtreatment outcome

Identifiers

PMID30421274
PMCPMC6292972
OpenAlexW2901270245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.